Kyverna Therapeutics Q2 EPS $(0.67) Misses $(0.64) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kyverna Therapeutics (NASDAQ:KYTX) reported a Q2 EPS of $(0.67), missing the analyst consensus estimate of $(0.64) by 4.69%.
August 12, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kyverna Therapeutics reported a Q2 EPS of $(0.67), missing the analyst consensus estimate of $(0.64) by 4.69%. This earnings miss could negatively impact the stock price in the short term.
The earnings miss indicates that the company's performance was below market expectations, which typically leads to a negative reaction from investors and a potential drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100